Literature DB >> 15561868

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.

Elizabeth Johnston1, Mark A Winters, Soo-Yon Rhee, Thomas C Merigan, Celia A Schiffer, Robert W Shafer.   

Abstract

We observed a previously uncharacterized mutation in the protease substrate cleft, L23I, in 31 of 4,303 persons undergoing human immunodeficiency virus type 1 genotypic resistance testing. In combination with V82I, L23I was associated with a sevenfold reduction in nelfinavir susceptibility and a decrease in replication capacity. In combination with other drug resistance mutations, L23I was associated with multidrug resistance and a compensatory increase in replication capacity.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15561868      PMCID： PMC529213          DOI： 10.1128/AAC.48.12.4864-4868.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Authors:  H C Côté; Z L Brumme; P R Harrigan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance.

Authors:  W Wang; P A Kollman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes.

Authors:  Moses Prabu-Jeyabalan; Ellen Nalivaika; Celia A Schiffer
Journal:  Structure       Date:  2002-03       Impact factor: 5.006

4.  On-going generation of multiple forms of HIV-1 intersubtype recombinants in the Yunnan Province of China.

Authors:  Rongge Yang; Xueshan Xia; Shigeru Kusagawa; Chiyu Zhang; Kunlong Ben; Yutaka Takebe
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

5.  Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Authors:  Thomas D Wu; Celia A Schiffer; Matthew J Gonzales; Jonathan Taylor; Rami Kantor; Sunwen Chou; Dennis Israelski; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Authors:  T Imamichi; S C Berg; H Imamichi; J C Lopez; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Authors:  S W Kaldor; V J Kalish; J F Davies; B V Shetty; J E Fritz; K Appelt; J A Burgess; K M Campanale; N Y Chirgadze; D K Clawson; B A Dressman; S D Hatch; D A Khalil; M B Kosa; P P Lubbehusen; M A Muesing; A K Patick; S H Reich; K S Su; J H Tatlock
Journal:  J Med Chem       Date:  1997-11-21       Impact factor: 7.446

8.  Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors.

Authors:  R W King; D L Winslow; S Garber; H T Scarnati; L Bachelor; S Stack; M J Otto
Journal:  Antiviral Res       Date:  1995-09       Impact factor: 5.970

9.  Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase.

Authors:  Lamei Chen; Alla Perlina; Christopher J Lee
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971
View more
  6 in total

1.  HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.

Authors:  Soo-Yon Rhee; W Jeffrey Fessel; Andrew R Zolopa; Leo Hurley; Tommy Liu; Jonathan Taylor; Dong Phuong Nguyen; Sally Slome; Daniel Klein; Michael Horberg; Jason Flamm; Stephen Follansbee; Jonathan M Schapiro; Robert W Shafer
Journal:  J Infect Dis       Date:  2005-07-05       Impact factor: 5.226

Review 2.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

3.  New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors.

Authors:  Madhavi N L Nalam; Celia A Schiffer
Journal:  Curr Opin HIV AIDS       Date:  2008-11       Impact factor: 4.283

4.  Molecular Basis for Drug Resistance in HIV-1 Protease.

Authors:  Akbar Ali; Rajintha M Bandaranayake; Yufeng Cai; Nancy M King; Madhavi Kolli; Seema Mittal; Jennifer F Murzycki; Madhavi N L Nalam; Ellen A Nalivaika; Ayşegül Özen; Moses M Prabu-Jeyabalan; Kelly Thayer; Celia A Schiffer
Journal:  Viruses       Date:  2010-11-12       Impact factor: 5.818

5.  Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.

Authors:  Lenka Besse; Andrej Besse; Sara C Stolze; Amin Sobh; Esther A Zaal; Alwin J van der Ham; Mario Ruiz; Santosh Phuyal; Lorina Büchler; Marc Sathianathan; Bogdan I Florea; Jan Borén; Marcus Ståhlman; Julia Huber; Arnold Bolomsky; Heinz Ludwig; J Thomas Hannich; Alex Loguinov; Bart Everts; Celia R Berkers; Marc Pilon; Hesso Farhan; Christopher D Vulpe; Herman S Overkleeft; Christoph Driessen
Journal:  Cancer Res       Date:  2021-06-22       Impact factor: 12.701

Review 6.  Viral protease inhibitors.

Authors:  Jeffrey Anderson; Celia Schiffer; Sook-Kyung Lee; Ronald Swanstrom
Journal:  Handb Exp Pharmacol       Date:  2009
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.